MDS experts, Dr Alan List and Dr David Sallman, describe the treatment cycle for azacitidine, a medication used for myelodysplastic syndromes (MDS). Treatment may be continued for as long as the patient continues to benefit. It is crucial that treatment decisions be made in consultation with your doctor, based on your personal situation.
This educational activity has been developed by
the Myelodysplastic Syndromes Foundation, Inc and Mechanisms in Medicine Inc.
This activity is supported by charitable grants from Celgene Corporation, Jazz Pharmaceuticals, Novartis, and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their health care professionals for optimal outcomes.